A Truncated Intracellular HER2/neu Receptor Produced by Alternative RNA Processing Affects Growth of Human Carcinoma Cells

REFERENCES

• Alper, O., K. Yamaguchi, J. Hitomi, S. Honda, T. Matsushima, and K. Abe. 1990. The presence of c-erbB-2 gene product- related protein in culture medium conditioned by breast cancer cell line SK-Br-3. Cell Growth Differ. 1:591–599.
   PubMedGoogle Scholar
• Bacus, S. S., E. Huberman, D. Chin, K. Kiguchi, S. Simpson, M. Lippman, and R. Lupu. 1992. A ligand for the erbB-2 oncogenic product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ. 3:401–411.
   PubMedGoogle Scholar
• Bacus, S. S., I. Stancovski, E. Huberman, D. Chin, E. Hurwitz, G. B. Mills, A. Ullrich, M. Sela, and Y. Yarden. 1992. Tumor inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res. 52:2580–2589.
   PubMed Web of Science ®Google Scholar
• Bargmann, C. I., M.-C. Hung, and R. Weinberg. 1986. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (London) 319:226–230.
   PubMed Web of Science ®Google Scholar
• Basu, A., R. M. Raghunath, S. Bishayee, and M. Das. 1989. Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol. Cell. Biol. 9:671–677.
   PubMedGoogle Scholar
• Coussens, L., T. L. Yang-Feng, Y.-C. Liao, E. Chen, A. Gray, J. McGrath, P. H. Seeburg, T. A. Libermann, J. Schlessinger, U. Francke, A. Levinson, and A. Ullrich. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139.
   PubMed Web of Science ®Google Scholar
• Downing, J. R., M. F. Roussel, and C. J. Sherr. 1989. Ligand and protein kinase C downmodulate the colony-stimulating factor 1 receptor by independent mechanisms. Mol. Cell. Biol. 9:2890–2896.
   PubMed Web of Science ®Google Scholar
• Engelhorn, S., and R. W. Raab. 1991. Rapid electroblotting of small fragments from polyacrylamide gels. BioTechniques 11:594–596.
   PubMedGoogle Scholar
• Fendly, B. M., C. Kotts, D. Vetterlein, G. D. Lewis, M. Winget, M. E. Carver, S. R. Watson, J. Sarup, S. Saks, A. Ullrich, and H. M. Shepard. 1990. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J. Biol. Response Modif. 9:449–455.
   PubMedGoogle Scholar
• Fendly, B. M., M. Winget, R. M. Hudziak, M. T. Lipari, M. A. Napier, and A. Ullrich. 1991. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50:1550–1558.
   Google Scholar
• Flickinger, T. W., N. J. Maihle, and H.-J. Kung. 1992. An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation. Mol. Cell. Biol. 12:883–893.
   PubMedGoogle Scholar
• Gubler, U., and B. J. Hoffmann. 1983. A simple and very efficient method for generating cDNA libraries. Gene 25:263–269.
   PubMed Web of Science ®Google Scholar
• Gullick, W. J., L. B. Love, C. Wright, D. M. Barnes, B. Gusterson, A. L. Harris, and D. G. Altman. 1991. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer 63:434–438.
   PubMed Web of Science ®Google Scholar
• Hancock, M. C., B. C. Langton, T. Chan, P. Toy, J. J. Monahan, R. P. Mischak, and L. K. Shawyer. 1991. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cisdiaminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51:4575–4580.
   PubMed Web of Science ®Google Scholar
• Holmes, W. E., M. X. Sliwkowski, R. W. Akita, W. J. Henzel, J. Lee, J. W. Park, D. Yansura, N. Abadi, H. Raab, G. D. Lewis, H. M. Shepard, W.-J. Kuang, W. I. Wood, D. V. Goeddel, and R. L. Vandlen. 1992. Identification of heregulin, a specific activator of p185erbB2. Science 256:1205–1210.
   PubMed Web of Science ®Google Scholar
• Huang, S. S., H. A. Koh, Y. Konish, L. D. Bullock, and J. S. Huang. 1990. Differential processing and turnover of the oncogenically activated neu/erbB2 gene product and its normal cellular counterpart. J. Biol. Chem. 265:3340–3346.
   PubMed Web of Science ®Google Scholar
• Hudziak, R. M·, G. D. Lewis, M. Winget, B. M. Fendly, H. M. Shepard, and A. Ullrich. 1989. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9:1165–1172.
   PubMed Web of Science ®Google Scholar
• Ishii, S., F. Imamoto, Y. Yamanashi, K. Toyoshima, and T. Yamamoto. 1987. Characterization of the promoter region of the human c-erbB-2 protooncogene. Proc. Natl. Acad. Sci. USA 84:4374–4378.
   PubMedGoogle Scholar
• Kashles, O., Y. Yardin, R. Fischer, A. Ullrich, and J. Schlessinger. 1991. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol. Cell. Biol. 11:1454–1463.
   PubMed Web of Science ®Google Scholar
• King, C. R., M. H. Kraus, and S. A. Aaronson. 1985. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976.
   PubMed Web of Science ®Google Scholar
• Kraus, M. H., N. C. Popescu, S. C. Amsbaugh, and C. R. King. 1987. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6:605–610.
   PubMed Web of Science ®Google Scholar
• Langton, B. C., M. C. Crenshaw, L. A. Chao, S. G. Stuart, R. W. Akita, and J. E. Jackson. 1991. An antigen immunologi-cally related to the external domain of gpl85 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res. 51:2593–2598.
   PubMedGoogle Scholar
• Leitzel, K., Y. Teramoto, E. L. Sampson, G. A. Wallingford, S. Weaver, L. Dcmcro, H. Harvey, and A. Lipton. 1991. Elevated c-erbB-2 levels in the serum and tumor extracts of breast cancer patients. Proc. Am. Assoc. Cancer Res. 32:997.
   Google Scholar
• Lin, Y. J., and G. M. Clinton. 1991. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 6:639–643.
   PubMed Web of Science ®Google Scholar
• Liu, E., G. Santos, W. Lee, C. K. Osborne, and C. Benz. 1989. Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. Oncogene 4:979–984.
   PubMedGoogle Scholar
• Loughnan, M. S., C. J. Sanderson, and G. J. V. Nossal. 1988. Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5. Proc. Natl. Acad. Sci. USA 85:3115–3119.
   PubMed Web of Science ®Google Scholar
• Lupu, R., R. Colomer, G. Zugmaier, J. Sarup, M. Shepard, D. Slamon, and M. E. Lippman. 1990. Direct interaction of a ligand for the erbB-2 oncogene product with the EGF receptor and pl85erbB-2. Science 249:1552–1555.
   PubMed Web of Science ®Google Scholar
• Maihle, N. J., T. W. Flickinger, M. A. Raines, M. L. Sanders, and H.-J. Kung. 1991. Native avian c-erbB gene expresses a secreted protein product corresponding to the ligand-binding domain of the receptor. Proc. Natl. Acad. Sci. USA 88:1825–1829.
   PubMed Web of Science ®Google Scholar
• McKenzie, S. E., M. A. Keller, D. L. Cassel, A. D. Schreiber, E. Schwartz, S. Surrey, and E. F. Rappaport. 1992. Characterization of the 5′-flanking transcriptional regulatory region of the human Fcγ receptor gene, FcγRIIA. Mol. Immunol. 29:1165–1174.
   PubMedGoogle Scholar
• Mosley, B., P. Beckmann, C. J. March, R. L. Idzerda, S. D. Gimple, T. VandenBos, D. Friend, A. Alpert, D. Anderson, J. Jackson, J. M. Wignall, C. Smith, B. Gallis, J. E. Sims, D. Urdal, M. B. Windmer, D. Cosman, and L. S. Park. 1989. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 59:335–3438.
   PubMed Web of Science ®Google Scholar
• Park, J. W., R. Stagg, G. D. Lewis, P. C. Carter, D. Maneval, D. J. Slamon, H. Jaffe, and H. M. Shepard. 1991. Anti-185HER2 monoclonal antibodies: biological properties and potential for immunotherapy, p. 193–211. In M. E. Lippman and R. B. Dickson (ed.), Genes, oncogenes, and hormones: advances in molecular biology of breast cancer. Kluwer, Boston.
   Google Scholar
• Peles, E., S. S. Bacus, R. A. Koski, H. S. Lu, D. Wen, S. G. Ogden, R. B. Levy, and Y. Yarden. 1992. Isolation of the neu/HER2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69:205–216.
   PubMed Web of Science ®Google Scholar
• Petch, L. A., J. Harris, V. W. Raymond, A. Biasband, D. C. Lee, and H. S. Earp. 1990. A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue. Mol. Cell. Biol. 10:2973–2982.
   PubMed Web of Science ®Google Scholar
• Rubin, L. A., C. C. Kurman, M. E. Fritz, W. E. Biddison, B. Boutin, R. Yarchoan, and D. L. Nelson. 1985. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 135:3172–3174.
   Google Scholar
• Scott, G. K., J. M. Dodson, P. A. Montgomery, R. M. Johnson, J. C. Sarup, W. L. Wong, A. Ullrich, H. M. Shepard, and C. C. Benz. 1991. pl85HER2 signal transduction in breast cancer cells. J. Biol. Chem. 266:14300–14305.
   PubMed Web of Science ®Google Scholar
• Semba, K., N. Kamata, K. Toyoshima, and T. Yamamoto. 1985. A v-erbB related proto-oncogene, c-erbB-2 is distinct from c-erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc. Natl. Acad. Sci. USA 82:6497–6501.
   PubMed Web of Science ®Google Scholar
• Slamon, D., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182.
   PubMed Web of Science ®Google Scholar
• Stancovski, L., E. Hurwitz, O. Leitner, A. Ullrich, Y. Yarden, and M. Sela. 1991. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB-2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA 88:8691–8695.
   PubMed Web of Science ®Google Scholar
• Tal, M., C. R. King, M. H. Kraus, A. Ullrich, J. Schlessinger, and D. Givol. 1987. Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation. Mol. Cell. Biol. 7:2597–2601.
   PubMedGoogle Scholar
• Yamamoto, T., S. Ikawa, T. Akiyama, K. Semba, N. Nomura, N. Miyajima, T. Saito, and K. Toyoshima. 1986. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature (London) 319:230–234.
   PubMed Web of Science ®Google Scholar
• Zabrecky, J. R., T. Lam, S. J. McKenzie, and W. Carney. 1991. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-Br-3. J. Biol. Chem. 266:1716–1720.
   PubMed Web of Science ®Google Scholar